Evonik, Rejects

Evonik Rejects BASF's 24-Euro Approach as BlackRock Trims Stake and Jefferies Turns Cautious

Published on 11/16/2026 at 13:11 | Editorial boerse-global.de
Evonik turned down BASF's €24-per-share takeover interest and is sticking to its standalone course, even after the two companies' top executives met.
Evonik, Rejects, BASFs, Approach, BlackRock, Trims, Stake, Jefferies, Turns, Cautious Illustration mit AI erstellt.

Evonik's refusal to entertain BASF's takeover interest has hardened into a firm position, with the specialty chemicals maker turning down an offer of 24 euros per share and insisting on going it alone. The stance held even after the chief executives and finance chiefs of both companies met in the Frankfurt area, a gathering sources described to Handelsblatt as purely informational. Reuters, citing insiders, reported on 9 November that no further meetings were initially planned, and that positions remained entrenched following the exchange.

The rebuff traces back to 30 October, when Evonik's management board rejected negotiations over BASF's expressed interest in a voluntary public takeover offer. At the same time, the board signalled it was open to a strictly informational and confidential dialogue — a channel that has so far produced no shift in its thinking.

BlackRock's Holding Slips Below Previous Threshold

On the shareholder register, BlackRock has reported a reduced voting stake in Evonik. A mandatory disclosure published today puts the total at 5.08%, down from 5.25% previously notified, with the threshold crossing dated 10 November. Voting rights attached to shares account for 3.94%, while a further 1.14% is attributed through instruments — a split the filing draws explicitly between direct equity holdings and positions held via derivatives.

Jefferies Steps Back From Buy Despite Higher Target

Analysts have been recalibrating their view even as the share price has firmed. Jefferies downgraded Evonik from "Buy" to "Hold" on 10 November, according to media reports, while simultaneously lifting its price target to 21 euros from 20 euros. The more cautious stance came with a 9% cut to the brokerage's 2027 EBITDA forecast, taking it below 2 billion euros. The message was mixed: a higher valuation marker paired with a less bullish recommendation.

Should investors sell immediately? Or is it worth buying Evonik?

The market, for its part, closed Friday at 21.14 euros, a gain of 0.9% that left the stock above Jefferies' newly raised target.

Earnings Momentum and a US Lipid Milestone

Operationally, Evonik has been delivering. On 3 November the company reported adjusted EBITDA of 629 million euros for the third quarter of 2026, a 40% increase on the prior-year period. For the full year, management expects adjusted EBITDA in the upper half of its guidance range of 2.0 to 2.2 billion euros.

Production milestones have followed. Evonik announced on 10 November the first GMP-grade batch of pharmaceutical lipids from its new Lipid Innovation Center in Lafayette, Indiana, with PhytoChol® as the inaugural product. Full production capacity is targeted by mid-2027.

Evonik at a turning point? This analysis reveals what investors need to know now.

Elsewhere in the business, Evonik Oxeno said on 9 November that it had introduced AI-based process optimisation into live plant operations, with initial applications expected to improve energy efficiency and cut CO? emissions. The same day, Evonik said it would present new specialty nutrition solutions at EuroTier 2026 in Hanover, running from 10 to 13 November, including Lypron® and ZyneXtra™.

Ad

Evonik Stock: New Analysis - 16 November

Fresh Evonik information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Evonik analysis...

Disclaimer...
en | DE000EVNK013 | EVONIK | boerse | 70520703 |